CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of its conference call at 8:00 a.m. EST on Wednesday, December 14, 2005. Millennium management will discuss VELCADE data from the 47th Annual Meeting of the American Society of Hematology being held in Atlanta, GA from December 10-13, 2006.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The live webcast can be accessed by visiting the Investors section of the Company's website, http://www.millennium.com/. Following the webcast, an archived version of the call will be available at the same address for 30 days.
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.
Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com/.
CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc., +1-617-761-4734
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html
COPYRIGHT 2005 PR Newswire Association LLC
COPYRIGHT 2005 Gale Group